Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian T Collins

Showing results (91-100 of 123) with videos related to

Pageof 13
Sort By:
Frontiers in Oncology|May 31, 2012
Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approachBeant Gill, Eric Oermann, Andrew Ju, et al.
Cureus|August 24, 2016
The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate CancerHarsha Koneru, Robyn Cyr, Li Rebekah Feng, et al.
Radiation Oncology (London, England)|April 19, 2015
Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancerMarie K Gurka, Leonard N Chen, Aditi Bhagat, et al.
Frontiers in Oncology|November 7, 2014
Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancerZaker Rana, Robyn A Cyr, Leonard N Chen, et al.
Frontiers in Oncology|June 1, 2016
Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose ReductionMichael C Repka, Shan Guleria, Robyn A Cyr, et al.
Frontiers in Oncology|April 8, 2024
Prognostic utility of biopsy-based <i>PTEN</i> and <i>ERG</i> status on biochemical progression and overall survival after SBRT for localized prostate cancerMichael C Repka, Tamir Sholklapper, Alan L Zwart, et al.
Diagnostic Cytopathology|August 7, 2012
A retrospective review of UroVysion fish interpretations over 8.6 years: a major shift in the patient test populationG Denice Smith, Nikhil A Sangle, Andrew Wilson, et al.
Journal of Hematology & Oncology|February 6, 2010
CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessmentSaloomeh Vahdat, Eric K Oermann, Sean P Collins, et al.
Radiation Oncology (London, England)|February 12, 2014
Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancerOnita Bhattasali, Leonard N Chen, Jennifer Woo, et al.
Frontiers in Oncology|April 18, 2022
Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate CancerMichael C Repka, Michael Creswell, Jonathan W Lischalk, et al.
Pageof 13

Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
Frontiers in Oncology|May 31, 2012
Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approachBeant Gill, Eric Oermann, Andrew Ju, et al.
Cureus|August 24, 2016
The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate CancerHarsha Koneru, Robyn Cyr, Li Rebekah Feng, et al.
Radiation Oncology (London, England)|April 19, 2015
Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancerMarie K Gurka, Leonard N Chen, Aditi Bhagat, et al.
Frontiers in Oncology|November 7, 2014
Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancerZaker Rana, Robyn A Cyr, Leonard N Chen, et al.
Frontiers in Oncology|June 1, 2016
Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose ReductionMichael C Repka, Shan Guleria, Robyn A Cyr, et al.
Frontiers in Oncology|April 8, 2024
Prognostic utility of biopsy-based <i>PTEN</i> and <i>ERG</i> status on biochemical progression and overall survival after SBRT for localized prostate cancerMichael C Repka, Tamir Sholklapper, Alan L Zwart, et al.
Diagnostic Cytopathology|August 7, 2012
A retrospective review of UroVysion fish interpretations over 8.6 years: a major shift in the patient test populationG Denice Smith, Nikhil A Sangle, Andrew Wilson, et al.
Journal of Hematology & Oncology|February 6, 2010
CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessmentSaloomeh Vahdat, Eric K Oermann, Sean P Collins, et al.
Radiation Oncology (London, England)|February 12, 2014
Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancerOnita Bhattasali, Leonard N Chen, Jennifer Woo, et al.
Frontiers in Oncology|April 18, 2022
Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate CancerMichael C Repka, Michael Creswell, Jonathan W Lischalk, et al.
Pageof 13